WE CLAIM:
1. A process of extracting the compound 5,7,4'-trihydroxy-6-(3-methylbut-2-enyl)-3'-(3-methylbut-2-enyl)-5'-(3-rnethylbut-2-enyl) isoflavone of Formula I

(Formula Removed)
from the plant Premna integrifolia Linn wherein the method comprises:
a. Collecting stem of Premna integrifolia
b. Drying the said stem,
c. Preparing an organic extract of the stem,
d. Concentrating the organic extract under reduced pressure at room temperature,
e. Suspending the organic extract in water and partitioning with organic solvent.
f. Drying the organic fractions over anhydrous sodium sulphate,
g. Concentrating the organic extract under reduced pressure
h. Subjecting the concentrated extract to the step of column chromatography; i. Eluting the extract with petroleum ether and petroleum ether-dichloromethane j. Pooling up the fractions enriched with compound of Formula I
k Subjecting the fractions enriched with compound of Formula I to a step of column chromatography
1. Purifying the enriched fractions by crystallization.
2. The process as claimed in claim 1, wherein the stem is air-dried upto 5 to 6 days
3. The process as claimed in claim 1, wherein the organic extract was prepared using organic
solvent selected from the group consisting of methanol, chloroform, dichloromethane or ethyl
acetate.
4. The process as claimed in claim 3, wherein the organic solvent is selected as methanol.
5. The process as claimed in claim 1, wherein partitioning was carried out in an organic solvent
is selected from the group consisting of hexane, petroleum ether, diethyl ether, toluene,
dichloromethane, dichloroethane, chloroform or ethyl acetate.
6. The process as claimed in claim 5, wherein the organic solvent is selected as petroleum
ether.
7. The process as claimed in claim 1, wherein the said column chromatography is performed
with petroleum ether: dichloromethane in a ratio of 9:1.
8. The process as claimed in claim 1, wherein the said column chromatography is performed
with petroleum ether: dichloromethane mixture in a ratio of 1:1.
9. The process as claimed in claim 1, wherein column chromatography of the fractions enriched
with compound of Formula I is performed with petroleum ether: ethyl acetate mixture in a ratio
49:1.
10. The process as claimed in claim 1, wherein column chromatography of the fractions enriched with compound of Formula I is performed with petroleum ether: ethyl acetate mixture in a ratio 9:1.
11. The process as claimed in claim 1, wherein the crystallization is carried out by using
petroleum ether: chloroform in a ratio of 9:1.
12. Use of compounds as defined in claim 1, in the manufacture of a medicament for treatment
or prophylaxis of an animal or a human suffering from disease or disorder mediated through
NFKB and PLA2.
13. The use according to claim 12, wherein the disease or disorder is inflammation.
14. The use according to claim 12, wherein the disease or disorder is AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis or ulcerative colitis.